Järfälla, Sweden

Emma Andersson

USPTO Granted Patents = 5 

Average Co-Inventor Count = 8.4

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • 71 Järfälla, SE (2010)
  • Järfälla, SE (2006 - 2013)
  • Jarfalla, SE (2014)

Company Filing History:


Years Active: 2006-2014

Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Journey of Inventor Emma Andersson

Introduction

Emma Andersson, an accomplished inventor from Järfälla, Sweden, has made significant contributions to the field of pharmaceuticals. With a total of five patents to her name, her work primarily focuses on therapeutic compounds aimed at treating serotonin-related disorders. Emma's innovative spirit and dedication to research have led to advancements in medications that impact the central nervous system.

Latest Patents

Emma Andersson's latest patents showcase her expertise in pharmaceutical compositions. One of her notable inventions is a pharmaceutical composition containing (2R)-methyl-1-3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinylpiperazine L-malate. This invention addresses processes for the preparation of compounds that are therapeutically active in the central nervous system. The specific focus is on the use of these compounds for manufacturing medicaments that target serotonin-related disorders.

Another significant patent is the (2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine and its salts, which also relates to compounds beneficial for the central nervous system. Both inventions emphasize the preparation of therapeutically active compounds and their subsequent use in treating disorders linked to serotonin.

Career Highlights

Throughout her career, Emma has worked with esteemed companies such as Biovitrum AB and Proximagen Limited. Her tenure at these organizations has enabled her to collaborate on groundbreaking research, ultimately leading to the development of innovative therapeutic solutions that improve patient outcomes.

Collaborations

Emma's journey as an inventor has been enriched by her collaborations with fellow researchers, including Magnus Cernerud and Margit Pelcman. These partnerships highlight the importance of teamwork in the research and development of new pharmaceuticals, reinforcing the value of shared knowledge and diverse perspectives in the innovative process.

Conclusion

Emma Andersson's contributions to pharmaceutical inventions stand as a testament to her dedication and innovative capabilities. With her continuous research in treating serotonin-related diseases, she is poised to make lasting impacts on the medical field. As she continues her work, Emma exemplifies the spirit of innovation that drives progress across various industries.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…